# MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

> **NCT00706238** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A

## Key facts

- **NCT ID:** NCT00706238
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-29
- **Primary completion:** 2011-01-19
- **Final completion:** 2011-01-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706238, "MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00706238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*